|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1700 GBX | +7.26% |
|
0.00% | -33.33% |
| 07-23 | WINNERS & LOSERS: capAI gains exclusive licence for Ageotype platform | AN |
| 07-21 | WINNERS & LOSERS: Harvest Minerals surges on Brazil portfolio takeover | AN |
| Market Cap | 4.44M 5.9M 5.19M 4.82M 8.32M 572M 8.47M 57.68M 22.5M 279M 22.16M 21.69M 967M | P/E 2024 |
-0.13x | P/E 2025 | -5.88x |
|---|---|---|---|---|---|
| Enterprise Value | 4.34M 5.77M 5.08M 4.72M 8.14M 559M 8.28M 56.41M 22M 273M 21.68M 21.21M 946M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
94.63% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/05/25 | Nuformix : Prospectus | PU |
| 05/10/23 | Nuformix to fund its unlicensed programs with NXP001 windfall | AQ |
| 20/12/22 | Nuformix hoping to "initiate discussions with major pharma" in 2023 | AQ |
| 20/12/22 | Nuformix hoping to 'initiate discussions with major pharma' in 2023 | EQ |
| 18/02/20 | Nuformix : Appointment of Dr Karl Keegan | PU |
| 1 day | +7.26% | ||
| Current month | -5.56% | ||
| 1 month | -11.23% | ||
| 3 months | -5.56% | ||
| 6 months | -38.18% | ||
| Current year | -33.33% |
| 1 week | 0.16 |  | 0.18 |
| 1 month | 0.16 | | 0.22 |
| Current year | 0.15 | | 0.4 |
| 1 year | 0.07 | | 0.56 |
| 3 years | 0.04 | | 0.56 |
| 5 years | 0.04 | | 1.93 |
| 10 years | 0.04 | | 14.89 |
| Manager | Title | Age | Since |
|---|---|---|---|
Shaun Zulafqar
SEC | Corporate Secretary | - | 29/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Daniel Gooding
CHM | Chairman | 53 | 05/02/2020 |
Julian Gilbert
CHM | Chairman | 65 | 28/07/2022 |
| Director/Board Member | 61 | 02/12/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 11/5/24 A | Free | Chairman | 22,000,000 | 2.6852% | ||
| 11/5/24 A | Free | Director | 22,000,000 | 2.6852% | ||
| 11/5/24 A | Free | Founder | 12,000,000 | 1.4646% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.26% | 0.00% | +94.29% | -33.33% | 5.53M | |
| +1.97% | +1.43% | +48.44% | +156.66% | 1,037B | |
| +1.42% | +3.72% | +53.32% | +52.34% | 615B | |
| +1.43% | +0.99% | +34.83% | +78.74% | 448B | |
| +5.14% | +5.40% | +33.75% | +27.28% | 326B | |
| +1.85% | +3.57% | +37.09% | +39.87% | 293B | |
| -0.11% | +0.48% | +18.87% | +17.81% | 264B | |
| +0.25% | -4.62% | -27.66% | -42.25% | 216B | |
| +1.49% | -0.02% | +20.14% | +58.21% | 198B | |
| +0.40% | -3.99% | +15.23% | +62.28% | 162B | |
| Average | +2.11% | +0.27% | +32.83% | +41.76% | 355.74B | |
| Weighted average by Cap. | +1.73% | +1.12% | +35.40% | +75.23% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -3.64M -4.85M -4.26M -3.96M -6.83M -469M -6.95M -47.35M -18.47M -229M -18.19M -17.8M -794M | -653K -868K -764K -710K -1.22M -84.1M -1.25M -8.48M -3.31M -41.02M -3.26M -3.19M -142M |
| Net Debt | -20.21K -26.89K -23.65K -21.97K -37.9K -2.6M -38.58K -263K -102K -1.27M -101K -98.78K -4.41M | -97.55K -130K -114K -106K -183K -12.57M -186K -1.27M -495K -6.13M -487K -477K -21.27M |
Employees
3
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/07/26 | GBX 0.1700 | +7.26% | 10,526,594 |
| 22/07/26 | GBX 0.1585 | -6.76% | 3,252,227 |
| 21/07/26 | GBX 0.1700 | +7.26% | 10,299,499 |
| 20/07/26 | GBX 0.1585 | -6.76% | 489,777 |
| 17/07/26 | GBX 0.1700 | 0.00% | 4,458,239 |
- Stock Market
- Stocks
- LVRT Stock
Select your edition
All financial news and data tailored to specific country editions
